Benjamin A Greenberger1, Margaret B Pulsifer2, David H Ebb3, Shannon M MacDonald4, Robin M Jones5, William E Butler6, Mary S Huang3, Karen J Marcus7, Jennifer A Oberg8, Nancy J Tarbell9, Torunn I Yock10. 1. Harvard Medical School, Boston, Massachusetts. 2. Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts. 3. Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts. 4. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. 5. Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts; Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts. 6. Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts. 7. Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts. 8. Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, New York. 9. Harvard Medical School, Boston, Massachusetts; Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. 10. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: tyock@partners.org.
Abstract
PURPOSE/OBJECTIVE(S): Primary low-grade gliomas are common brain tumors of childhood, many of which require radiation therapy (RT) as definitive treatment. Increased conformality of RT could decrease the incidence and severity of late effects. We report our experience with 32 pediatric patients treated with proton RT. METHODS AND MATERIALS: Thirty-two pediatric patients with low-grade gliomas of the brain or spinal cord were treated with proton RT from 1995 to 2007. Sixteen patients received at least 1 regimen of chemotherapy before definitive RT. The median radiation dose was 52.2 GyRBE (48.6-54 GyRBE). RESULTS: The median age at treatment was 11.0 years (range, 2.7-21.5 years), with a median follow-up time of 7.6 years (range, 3.2-18.2 years). The 6-year and 8-year rates of progression-free survival were 89.7% and 82.8%, respectively, with an 8-year overall survival of 100%. For the subset of patients who received serial neurocognitive testing, there were no significant declines in Full-Scale Intelligence Quotient (P=.80), with a median neurocognitive testing interval of 4.5 years (range, 1.2-8.1 years) from baseline to follow-up, but subgroup analysis indicated some significant decline in neurocognitive outcomes for young children (<7 years) and those with significant dose to the left temporal lobe/hippocampus. The incidence of endocrinopathy correlated with a mean dose of ≥40 GyRBE to the hypothalamus, pituitary, or optic chiasm. Stabilization or improvement of visual acuity was achieved in 83.3% of patients at risk for radiation-induced injury to the optic pathways. CONCLUSIONS: This report of late effects in children with low-grade gliomas after proton RT is encouraging. Proton RT appears to be associated with good clinical outcome, especially when the tumor location allows for increased sparing of the left temporal lobe, hippocampus, and hypothalamic-pituitary axis.
PURPOSE/OBJECTIVE(S): Primary low-grade gliomas are common brain tumors of childhood, many of which require radiation therapy (RT) as definitive treatment. Increased conformality of RT could decrease the incidence and severity of late effects. We report our experience with 32 pediatric patients treated with proton RT. METHODS AND MATERIALS: Thirty-two pediatric patients with low-grade gliomas of the brain or spinal cord were treated with proton RT from 1995 to 2007. Sixteen patients received at least 1 regimen of chemotherapy before definitive RT. The median radiation dose was 52.2 GyRBE (48.6-54 GyRBE). RESULTS: The median age at treatment was 11.0 years (range, 2.7-21.5 years), with a median follow-up time of 7.6 years (range, 3.2-18.2 years). The 6-year and 8-year rates of progression-free survival were 89.7% and 82.8%, respectively, with an 8-year overall survival of 100%. For the subset of patients who received serial neurocognitive testing, there were no significant declines in Full-Scale Intelligence Quotient (P=.80), with a median neurocognitive testing interval of 4.5 years (range, 1.2-8.1 years) from baseline to follow-up, but subgroup analysis indicated some significant decline in neurocognitive outcomes for young children (<7 years) and those with significant dose to the left temporal lobe/hippocampus. The incidence of endocrinopathy correlated with a mean dose of ≥40 GyRBE to the hypothalamus, pituitary, or optic chiasm. Stabilization or improvement of visual acuity was achieved in 83.3% of patients at risk for radiation-induced injury to the optic pathways. CONCLUSIONS: This report of late effects in children with low-grade gliomas after proton RT is encouraging. Proton RT appears to be associated with good clinical outcome, especially when the tumor location allows for increased sparing of the left temporal lobe, hippocampus, and hypothalamic-pituitary axis.
Authors: Anthony P Y Liu; Camden Hastings; Shengjie Wu; Johnnie K Bass; Andrew M Heitzer; Jason Ashford; Robert Vestal; Mary E Hoehn; Yahya Ghazwani; Sahaja Acharya; Heather M Conklin; Frederick Boop; Thomas E Merchant; Amar Gajjar; Ibrahim Qaddoumi Journal: Cancer Date: 2019-01-08 Impact factor: 6.860
Authors: Susan L McGovern; M Fatih Okcu; Mark F Munsell; Nancy Kumbalasseriyil; David R Grosshans; Mary F McAleer; Murali Chintagumpala; Soumen Khatua; Anita Mahajan Journal: Int J Radiat Oncol Biol Phys Date: 2014-10-11 Impact factor: 7.038
Authors: Joel M Cherlow; Dennis W W Shaw; Linda R Margraf; Daniel C Bowers; Jie Huang; Maryam Fouladi; Arzu Onar-Thomas; Tianni Zhou; Ian F Pollack; Amar Gajjar; Sandy K Kessel; Patricia L Cullen; Kevin McMullen; John C Wellons; Thomas E Merchant Journal: Int J Radiat Oncol Biol Phys Date: 2018-11-10 Impact factor: 7.038
Authors: Matthew W Parsons; Nicholas S Whipple; Matthew M Poppe; Joe S Mendez; Donald M Cannon; Lindsay M Burt Journal: J Neurooncol Date: 2020-10-31 Impact factor: 4.130
Authors: Julie A Grieco; Annah N Abrams; Casey L Evans; Torunn I Yock; Margaret B Pulsifer Journal: Childs Nerv Syst Date: 2019-07-19 Impact factor: 1.475
Authors: Matthew M Ladra; Henry C Mandeville; Andrzej Niemierko; Timothy P Padera; Alison M Friedmann; Shannon M MacDonald; David Ebb; Yen-Lin Chen; Nancy J Tarbell; Torunn I Yock Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-08 Impact factor: 7.038
Authors: Sahaja Acharya; Jo-Fen Liu; Ruth G Tatevossian; Jason Chiang; Ibrahim Qaddoumi; Amar Gajjar; David Walker; Julie H Harreld; Thomas E Merchant; David W Ellison Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300
Authors: Alexandra K Roth; M Douglas Ris; Jessica Orobio; Judy Xue; Anita Mahajan; Arnold C Paulino; David Grosshans; M Fatih Okcu; Murali Chintagumpala; Lisa S Kahalley Journal: Pediatr Blood Cancer Date: 2019-11-17 Impact factor: 3.167
Authors: Margaret B Pulsifer; Roshan V Sethi; Karen A Kuhlthau; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock Journal: Int J Radiat Oncol Biol Phys Date: 2015-06-14 Impact factor: 7.038